Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003188 | 0.91 | GAA (0.44) | GAAMAP2K1HDAC3HDAC1HDAC6 | |
| SCHEMBL3999168 | 0.87 | MAP2K1 (0.49) | MAP2K1 | |
| SCHEMBL1216151 | 0.86 | MAP2K1 (0.44) | GAAMAP2K1DYRK1ANPC1ALDH1A1 | |
| SCHEMBL1215968 | 0.84 | MAP2K1 (0.38) | GAAMAP2K1ALDH1A1 | |
| SCHEMBL1217020 | 0.80 | MAP2K1 (0.56) | MAP2K1 | |
| SCHEMBL3997430 | 0.78 | MAP2K1 (0.48) | MAP2K1 | |
| SCHEMBL1216500 | 0.77 | MAP2K1 (0.44) | GAAMAP2K1DYRK1AALDH1A1SMN1; SMN2 | |
| SCHEMBL12895503 | 0.77 | MAP2K1 (0.41) | GAAMAP2K1 | |
| SCHEMBL12883214 | 0.77 | MAP2K1 (0.51) | MAP2K1 | |
| SCHEMBL2563035 | 0.76 | MAP2K1 (0.56) | GAAMAP2K1NPC1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069359-B1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2069359-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| WO-2008024724-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | GAA 1805/4885MAP2K1 38/4885DYRK1A 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.